Cellipont, Diakonos Oncology Partner on Glioblastoma Therapy

Cellipont Bioservices, a contract development and manufacturing organization (CDMO), entered into an agreement with Diakonos Oncology for the process development and cGMP manufacturing of DOC1021, an autologous dendritic cell vaccine being manufactured for the treatment of glioblastoma multiforme (GBM) and other cancer indications.

With a first of its kind approach, Diakonos’ DOC1021 activates a natural anti-viral immune response against a patient’s tumor. Due to the promising results in both safety and efficacy in its phase 1 trial, Diakonos recently received fast track designation by the FDA.

“We are deeply honored to have been chosen as Diakonos’ partner in this critical endeavor,” said Darren Head, chairman of the board of Cellipont Bioservices. “With our extensive expertise in cell therapy development and manufacturing, coupled with our purpose-built Woodlands facility, we are confident that our collaboration will pave the way for bringing this life-saving therapy to countless glioblastoma patients.”

Mike Wicks, CEO of Diakonos said, “As DOC1021 is personalized to each patient, it was critical to find a CDMO partner that could not only help commercialize this incredibly promising treatment but exceed our quality standards for each and every patient. We could not be happier to find that partner in Cellipont, and we look forward to changing patient outcomes in GBM as well as other cancer indications.”